SynthesisJournal of neuro-oncology2020
Current status and treatment modalities in metastases to the pituitary: a systematic review.
Synthesis in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Stereotactic radiosurgery in pituitary metastases: a systematic review and meta-analysis.Radiation oncology (London, England) · 2025Pooled it
- Diabetes Insipidus as a Rare Complication of Metastatic Breast Cancer With Pituitary Metastases.Cureus · 2026Article
- Central Diabetes Insipidus as a Rare Presentation of Small Cell Lung Cancer: A Case Report.Cureus · 2026Article
- Pituitary Metastasis in Lung Cancer Patients: Case Series and Review of the Literature.Current oncology (Toronto, Ont.) · 2026Review
- A sellar mass as the initial presentation of pituitary infiltration by diffuse large B-cell lymphoma: a case report.Frontiers in oncology · 2026Article
- Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Caused by Pola-R-CHOP: A Case Report.Cureus · 2025Article
- Pituitary and pineal gland metastases from pulmonary neuroendocrine carcinoma: A case report and literature review.Molecular and clinical oncology · 2025Article
- Outcomes of stereotactic radiosurgery for pituitary metastases: an international multi-institutional study.Pituitary · 2025Article
- Article
- [Metastatic pituitary lesion].Problemy endokrinologii · 2024Article
- Solitary pituitary metastasis from breast cancer masquerading as a pituitary macroadenoma: a report of 2 rare cases.Gland surgery · 2024Article
- Distinguishing Pituitary Metastasis and Pituitary Neuroendocrine Tumors through Conventional MR Imaging and Clinical Features.AJNR. American journal of neuroradiology · 2024Article
- Pituitary metastasis from lung adenocarcinoma: A case report.World journal of clinical cases · 2024Article
- Metastases to the pituitary gland: insights from the German pituitary tumor registry.Pituitary · 2023Article
- Diabetes Insipidus due to Metastases of Undiagnosed Lung Cancer: A Case Report from Syria.Case reports in endocrinology · 2023Article
- The role of stereotactic radiosurgery in the multidisciplinary management of pituitary metastases.Pituitary · 2022Article
- Article
- Masked diabetes insipidus in pituitary metastasis from breast cancer after thalamic biopsy: a case report.Journal of medical case reports · 2022Article
- Unusual presentation of lung carcinoma with pituitary metastasis: a challenging diagnosis and sodium management dilemmas.Endocrine oncology (Bristol, England) · 2022Article
- Apoplexy in sellar metastasis from papillary thyroid cancer: A case report and literature review.Surgical neurology international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetastases to the pituitary (MP) are uncommon, accounting for 0.4% of intracranial metastases. Through advances in neuroimaging and oncological therapies, patients with metastatic cancers are living longer and MP may be more frequent. This review aimed to investigate clinical and oncological features, treatment modalities and their effect on survival.
methodsA systematic review was performed according to PRISMA recommendations. All cases of MP were included, excepted primary pituitary neoplasms and autopsy reports. Descriptive and survival analyses were then conducted.
resultsThe search identified 2143 records, of which 157 were included. A total of 657 cases of MP were reported, including 334 females (50.8%). The mean ± standard deviation age was 59.1 ± 11.9 years. Lung cancer was the most frequent primary site (31.0%), followed by breast (26.2%) and kidney cancers (8.1%). Median survival from MP diagnosis was 14 months. Overall survival was significantly different between lung, breast and kidney cancers (P < .0001). Survival was impacted by radiotherapy (hazard ratio (HR) 0.49; 95% confidence interval (CI) 0.35-0.67; P < .0001) and chemotherapy (HR 0.58; 95% CI 0.36-0.92; P = .013) but not by surgery. Stereotactic radiotherapy tended to improve survival over conventional radiotherapy (HR 0.66; 95% CI 0.39-1.12; P = .065). Patients from recent studies (≥ 2010) had longer survival than others (HR 1.36; 95% CI 1.05-1.76; P = .0019).
conclusionThis systematic review based on 657 cases helped to better identify clinical features, oncological characteristics and the effect of current therapies in patients with MP. Survival patterns were conditioned upon primary cancer histologies, the use of local radiotherapy and systemic chemotherapy, but not by surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.